Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AbbVie

Abbott Labs

Abbott Laboratories is a Dividend King with a diverse business. Amgen offers a high dividend yield plus a track record of innovation.

3 Unstoppable Dividend Stocks to Buy Right Now

First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. , Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use.

OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS

Johnson & Johnson

The Dow Jones Industrial Average contains shares of 30 companies that lead their respective industries. Now that it no longer sells consumer goods, Johnson & Johnson's dividend growth rate could shift into a higher gear.

2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade

Amgen generated 20% revenue growth in its most recent quarter. The business has several fast-growing drugs showing double-digit growth despite generating over $200 million in quarterly sales.

This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline

UnitedHealth Group

Let's talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one. Here at Contrarian Outlook we have been preparing for slower economic readings, and our recession divvies have already delivered.

3 ‘Recession-Resistant' Dividends Growing Up To 12% Annually

Amgen Inc., the Thousand Oaks headquartered Pharma giant, reported its Q2 2024 earnings on August 6th. My last coverage of Amgen was in May after Q1 earnings, and I awarded the stock a “buy” recommendation. Q2 earnings were generally solid, with the Horizon assets bedding in well, meaning revenues grew 20% year-on-year.

Amgen: Q2 Earnings Review: Still Solid, But Wait For MariTide Data Goes On

Apple

Ares Capital

Home Depot

Coca-Cola

Lockheed Martin

Microsoft

Vici Properties

Times of higher uncertainty and elevated market volatility can provide investors with excellent opportunities to start building a dividend portfolio. The dividend portfolio I will present in today's article provides investors with broad diversification across sectors, with no sector accounting for more than 18% of the overall portfolio. This dividend portfolio delivers a Weighted Average Dividend Yield [TTM] of 3.90% and a 5-year Weighted Average Dividend Growth Rate of 8.69%.

Building A $100,000 Dividend Portfolio With 3 ETFs And 3 Stocks

Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance.

Amgen Stock Slides on Lowered Guidance

BMO Capital Markets writes, “A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in obesity and inflammatory disease.” The analyst keeps the Outperform rating with a price target of $362.

Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts

The pharmaceutical company's second-quarter numbers were roughly in line with expectations. Amgen's slight earnings miss, however, was enough to spark a sizeable sell-off.

Why Amgen Stock Is Down Today Despite Solid Q2 Results

Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024.

Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat

Amgen NASDAQ: AMGN is a biotechnology firm that has made its way into the weight loss treatment battle. The company's shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market.

Amgen's MariTide Weight Loss Potential: Stock Outlook

Amgen Inc. (NASDAQ:AMGN ) Q2 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Bob Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Jay Bradner - EVP, Research and Development & Chief Scientific Officer Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Mike Yee - Jefferies Umer Raffat - Evercore ISI Jay Olson - Oppenheimer Mohit Bansal - Wells Fargo Gregory Renza - RBC Capital Markets Chris Raymond - Piper Sandler Carter Gould - Barclays Terence Flynn - Morgan Stanley Chris Schott - JPMorgan Kripa Devarakonda - Truist Securities James Shin - Deutsche Bank Gary Nachman - Raymond James Operator My name is Julianne, and I will be your conference facilitator today for Amgen's Second Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.

Amgen Inc. (AMGN) Q2 2024 Earnings Call Transcript

The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say

Amgen (AMGN) came out with quarterly earnings of $4.97 per share, beating the Zacks Consensus Estimate of $4.93 per share. This compares to earnings of $5 per share a year ago.

Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates

Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat.

Amgen Is Redoubling Its Efforts To Take On Weight-Loss Kingpins Novo, Lilly

Amgen on Tuesday said its second-quarter profit slipped 1% as higher expenses offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.

Amgen second quarter profit dips, sales rise 20%

THOUSAND OAKS, Calif. , Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024.

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Amgen Inc. AMGN is expected to release earnings results for its second quarter, after the closing bell on Tuesday, Aug. 6.

Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dow Jones biotech giant Amgen, along with MercadoLibre, Ferrari and Lennar, are in or near buy zones in today's stock market sell-off.

Dow Jones Biotech Amgen, MercadoLibre, Ferrari Hold Up In Shaken Market

Gilead Sciences

Eli Lilly

Novo Nordisk

Viatris

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

THOUSAND OAKS, Calif. , Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024.

AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND

Terns Pharmaceuticals

Vertex Pharmaceuticals

Investing in biotech stocks is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their investigational therapies fail to make it to market.

3 Biotech Stocks That Could Have Investors Grinning Soon

Amgen is developing a promising anti-obesity candidate. This product could be a blockbuster by 2030.

Prediction: This Could Be Amgen's Next Massive Growth Opportunity

Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.

News for Amgen Stock (AMGN)